Gene-Modified Stem Cell Therapy for Subjects With Transfusion-dependent Beta-thalassemia

NCT07680803 | Recruiting Phase 2 DMC

• 2 other identifiers: BTHAL-FT007-012025-522160-32-00
• Study Type: interventional
• Target: 9
• Locations: 1 country
• Sites: 2

Brief Summary

This is a prospective, dual-centre, single dose, Phase IIb, single arm, open label study. The proposed clinical trial involves a single infusion of autologous HSPCs genetically modified with the GLOBE lentiviral vector, using an improved transduction protocol in 9 patients affected by transfusion dependent Beta-Thalassemia. Four study phases are foreseen:

1. 1.Screening phase, during which the conditions required by the clinical protocol for patients' inclusion/exclusion will be assessed after the signature of the informed consents/assents. Patients will be recruited from the two participating sites: IRCCS Ospedale San Raffaele (OSR), Department of Pediatric Immunohematology and adult Hematology (OSR Stem Cells Programme) (Milan) and IRCCS Ospedale Pediatrico Bambino Gesù (OPBG), Department of Haematology, Oncology and Gene and Cell Therapy (Rome).
2. 2.Baseline phase, carried from the end of the screening phase to the day before the start of the conditioning regimen.
3. 3.Treatment phase, from the first day of conditioning regimen until DP administration.
4. 4.Follow-up phase: from DP administration until 2 years follow-up.

Conditions

Transfusion-dependent Beta-Thalassemia

Outcome Measures

Primary Outcomes (1)

• Proportion of subjects who achieve TI12 in the 2 years from DP administration

  Proportion of Subjects achieving transfusion independence defined as a weighted average Hb ≥ 9.0 gr/dL without any red blood cell transfusion for a continuous period of ≥ 12 months (TI12) at any time during the study after the drug product administration The assessment of TI12 starts 60 days after last RBC transfusion for post-transplant support or BTHAL standard of care.

  from 60 days after the IMP infusion, to 24 months of follow-up

Secondary Outcomes (19)

• Overall survival

  12 months and 24 months post IMP infusion

• Proportion of Subjects who achieve hematological engraftment ≤ day +60 from DP administration

  from Day 11 to Day 60 post IMP infusion

• Frequency and severity of adverse events (AEs) and serious adverse events (SAEs) (Safety and tolerability of the administration of FT007)

  from Baseline to 24 months post IMP infusion

• Proportion of Subjects with abnormal clonal proliferation development due to insertional mutagenesis

  6, 12, 18 and 24 months post IMP infusion

• Polyclonal and multilineage engraftment evaluated by VCN and ISA

  screening, 1, 2, 3, 6, 12, 18 and 24 months after IMP infusion

Study Arms (1)

subjects with transfusion-dependent beta-thalassemia

EXPERIMENTAL

Genetic: FT007

Interventions

FT007 GENETIC

Autologous hematopoietic stem and progenitor cells (HSPCs) transduced ex vivo with the lentiviral vector GLOBE encoding for the human beta globin using an improved transduction protocol, re-suspended in their final formulation medium and cryopreserved.

subjects with transfusion-dependent beta-thalassemia

Eligibility Criteria

• Age: 3 Years - 35 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Must be willing to adhere to the protocol as evidenced by written informed consent for adults or parental informed consent and subject assent for adolescents and children.
• Male and female adults/adolescents/children diagnosed with transfusion-dependent β-thalassemia (homozygous or compound heterozygous). At least 2 out of the 9 patients must have B0/B0 or B0/B0-like genotype. In case the genetic diagnosis available at screening wasn't performed in a certified laboratory (check under PI's or delegated investigator's responsibility), the genetic diagnosis will be repeated at clinical sites during the screening phase.
• Documented history of at least 100 ml/kg/year or 10 U/year of packed red blood cell transfusions in each of the 2 years prior to signing informed consent.
• Age ≥ 18 years and ≤ 35 years for Group 1, Age ≥ 3 years and ≤ 35 years for Group 2.
• Karnofsky Index or Lansky ≥ 80%.
• Adequate cardiac, renal, hepatic and pulmonary functions resulting in eligibility to undergo autologous HSCT as evidenced by:
• Left ventricular ejection fraction (LVEF) greater than 45% by echo and normal ECG or presence of abnormalities not significant for cardiac disease. Absence of severe pulmonary hypertension.
• Diffusing capacity of the lung for carbon monoxide (DLCO) \> 50% and forced expiratory volume in 1 sec (FEV1) and forced expiratory vital capacity (FVC) \> 60% predicted (if non cooperative: pulse oximetry \> 95 % in room air).
• Serum creatinine \< 2 x upper limit of normal and estimated GFR \> 60 ml/min/1.73m2, calculated using the CKD-EPI formula (Levey 2009) for adults and the modified Schwartz formula (Schwartz 2009) for pediatric patients.
• Absent-mild-moderate liver iron overload on T2\*MRI (i.e. LIC \< 15 mg Fe/gr dry weight assessed at screening. T2\*MRI at screening can be avoided if performed less than 6 months before enrolment at treatment centers).
• Absent-mild-moderate cardiac iron overload T2\*MRI (i.e. \> 20 msec assessed at screening. T2\*MRI at screening can be avoided if performed less than 6 months before enrolment at treatment centers).
• Absence of severe liver fibrosis or cirrhosis on Shear Wave (less than 6 months before enrolment) or of other advanced liver disorder.
• For all patients in reproductive age, agreement to use highly effective and adequate method of contraception for at least 12 months following DP administration (including both females of childbearing potential and males with partners of childbearing potential).
• Good adherence to transfusion and chelation programme, as indirect evidence of good adherence to treatment and follow-up evaluations for the current trial.
• Availability of an adequate and well documented transfusion history (at least previous 24 months) or availability to follow a regular transfusion regimen according to guidelines and provide a detailed transfusion record of the 24 months prior to the DP administration.

You may not qualify if:

• Use of other investigational agents within 4 weeks prior to study enrolment (within 6 weeks if use of long-acting agents).
• Severe, active viral, bacterial or fungal infection at eligibility evaluation.
• Current or prior malignant neoplasia (except local skin cancer or cervical intraepithelial neoplasia) or exceptional family history of familial cancer syndromes.
• Current or prior immunodeficiency disorder.
• History of uncontrolled seizures.
• Aspartate transaminase (AST), alanine transaminase (ALT) \>3 × the upper limit of normal (ULN), or direct bilirubin value \>2.5 × ULN.
• Baseline prothrombin time (International Normalized Ratio; INR) \>1.5 × ULN.
• Other clinical conditions judged non compatible with the procedure and/or the treatment.
• Positivity for HIV (serology or RNA), and/or HbsAg and/or HBV DNA and/or HCV RNA (patients who have completed antiviral treatment for HCV may only be enrolled if they have achieved a sustained virologic response, defined as undetectable HCV RNA at least 12 weeks after completion of therapy) and/or evidence of active infection of Treponema Pallidum or Mycoplasma species.
• Active alcohol or substance abuse within 6 months of the study.
• Pregnancy or lactation.
• Previous allogeneic hematopoietic stem cell transplantation.
• Previous gene therapy treatment (gene addition or gene editing).
• For patients until the age of 14 years only: availability of an HLA-matched family donor.
• Patients with associated α-thalassemia and \>1 alpha deletion, or alpha multiplications.

Sponsors & Collaborators

• Ospedale San Raffaele: collaborator
• Fondazione Telethon: lead

Study Sites (2)

Ospedale Pediatrico Bambino Gesù

Rome, Lazio, 00165, Italy

RECRUITING

Ospedale San Raffaele

Milan, Lombardy, 20132, Italy

RECRUITING

Central Study Contacts

Alessandro Aiuti, Professor

CONTACT

+39 02 26439057; aiuti.alessandro@hsr.it

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 25, 2026
• First Posted: July 2, 2026
• Study Start: July 6, 2026
• Primary Completion (Estimated): October 1, 2028
• Study Completion (Estimated): October 1, 2030
• Last Updated: July 27, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share

Locations

IT (2)